Roivant Sciences Ltd.ROIVEarnings & Financial Report

Nasdaq · pharmaceutical industry

Roivant Sciences Ltd. is an American multinational healthcare company focused on applying technology to drug development and building subsidiary life sciences and health technology companies. It was founded in 2014 by Vivek Ramaswamy and is currently headed by CEO Matt Gline. Roivant maintains its headquarters in New York City as well as major offices in the biotech hubs of Boston and Basel.

Revenue

$2.0M

Gross Profit

N/A

Operating Profit

$-339.2M

Net Profit

$-265.9M

Gross Margin

N/A

Operating Margin

-16966.1%

Net Margin

-13301.2%

YoY Growth

-77.8%

EPS

$-0.38

Financial Flow

Roivant Sciences Ltd. Q3 2026 Financial Summary

Roivant Sciences Ltd. reported revenue of $2.0M for Q3 2026, with a net profit of $-265.9M (-13301.2% margin). Cost of goods sold was N/A, operating expenses totaled N/A.

Key Financial Metrics

Total Revenue	$2.0M
Net Profit	$-265.9M
Gross Margin	N/A
Operating Margin	-16966.1%
Report Period	Q3 2026

Roivant Sciences Ltd. Annual Revenue by Year

Roivant Sciences Ltd. annual revenue history includes year-by-year totals (for example, 2025 revenue was $29.1M).

Year	Annual Revenue
2025	$29.1M
2024	$124.8M
2023	$61.3M
2022	$55.3M

Income Statement

	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Revenue	$28.9M	$55.1M	$4.5M	$9.0M	$-39.6M	$2.2M	$1.6M	$2.0M
YoY Growth	5.7%	155.0%	-87.9%	-75.7%	-236.8%	-96.1%	-64.9%	-77.8%

Balance Sheet

	Q4 2024	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026	Q3 2026
Assets	$7.22B	$6.50B	$6.21B	$5.79B	$5.44B	$5.03B	$5.06B	$5.23B
Liabilities	$774.0M	$601.2M	$626.0M	$256.4M	$249.7M	$216.7M	$257.1M	$251.1M
Equity	$5.97B	$5.44B	$5.15B	$5.19B	$4.69B	$4.35B	$4.36B	$4.27B